March 2020, Volume 6, Issue 4

March 2020

Volume 6, Issue 4

This issue looks at how cost-effective analyses are used to inform health-care decisions, explains the latest maintenance of certification requirements, and more.

Table of Contents

March 2020 Issue

You Make the Call

Reader Responses: What is the best consolidation therapy for this patient with primary central...

Sunday, March 1st, 2020
Here’s how readers responded to a You Make the Call question about the treatment of primary central nervous system lymphoma. Disclaimer: ASH does not recommend...

How Science Informs Advocacy

Sunday, March 1st, 2020
Last year, the American Society of Hematology (ASH) selected Zachary Kiser, PhD, as its 2019-2020 ASH Congressional Fellow. The program aims to connect hematologists...

Visions of the Future

Sunday, March 1st, 2020
In our January issue, new ASH Clinical News Editor-in-Chief David Steensma, MD, reflected on the reputation of the year 2020, a date frequently used...

Editor’s Corner: The China Conundrum

Sunday, March 1st, 2020
As I begin writing this editorial, nanoscience expert Charles Lieber, PhD, Chair of Harvard University’s Department of Chemistry and Chemical Biology, is sitting in...

March 2020 Issue

FDA Grants Belantamab Mafodotin Priority Review for Myeloma

Sunday, March 1st, 2020
The FDA granted priority review to the biologics license application of belantamab mafodotin for the treatment of patients with relapsed or refractory multiple myeloma...

Sickle Cell Disease Gene Therapy Receives Orphan Drug Designation

Sunday, March 1st, 2020
ARU-1801, an investigational gene therapy for the treatment of sickle cell disease (SCD) and beta thalassemia, was granted orphan drug designation by the FDA. ARU-1801...
WIB_icon

Avadomide Shows Promising Clinical Activity and Tolerability in Relapsed/Refractory DLBCL

Sunday, March 1st, 2020
Avadomide monotherapy demonstrated preliminary clinical efficacy in patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL), according to results from a phase I...
WIB_icon

Peripherally Inserted Central Catheters Sharply Increase Risk of Childhood VTE Events

Sunday, March 1st, 2020
In children who received central venous catheters, peripherally inserted central catheters (PICCs) appear to be associated with a higher risk of venous thromboembolism (VTE),...

BioMarin Sets High Price Tag for Hemophilia Gene Therapy Candidate

Sunday, March 1st, 2020
If its experimental gene therapy for patients with hemophilia A is approved by the FDA, BioMarin Pharmaceutical is considering pricing valoctocogene roxaparvovec (valrox) between...
Sickle cell anemia

ICER Report Finds That Sickle Cell Drugs Are Too Expensive

Sunday, March 1st, 2020
According to a draft report by the Institute for Clinical and Economic Review (ICER), SCD drugs made by Novartis, Global Blood Therapeutics (GBT), and...

The MAGIC Marker: Measurements of Two Serum Biomarkers Predict GVHD Treatment Response

Sunday, March 1st, 2020
Measuring damage to crypts in the gastrointestinal tract during graft-versus-host disease (GVHD) via the Mount Sinai Acute GVHD International Consortium (MAGIC) algorithm probability (MAP)...

How Common Is Serotonin Release Assay-Negative Heparin-Induced Thrombocytopenia?

Sunday, March 1st, 2020
Heparin-induced thrombocytopenia (HIT), a prothrombotic drug reaction caused by platelet-activating anti-platelet factor 4 (PF4)/heparin antibodies, is commonly diagnosed with the platelet serotonin-release assay (SRA)...

Early Peripheral Blast Cell Clearance Predicts Response to Induction Chemotherapy in Acute Myeloid Leukemia

Sunday, March 1st, 2020
Early peripheral blast cell clearance (PBC) assessed by leukocyte differential is well established as a predictor of leukemia induction outcome, but measuring PBC by...

FDA Approves Ferric Derisomaltose for Iron-Deficiency Anemia

Sunday, March 1st, 2020
The ferric derisomaltose injection received FDA approval for the treatment of iron-deficiency anemia in adults who are intolerant to oral iron, whose disease has...

A 42-Item Frailty Index Improves Survival Prediction in Myelodysplastic Syndromes

Sunday, March 1st, 2020
In a recent Leukemia paper, researchers reported on a new 42-variable frailty index (FI) for patients with myelodysplastic syndromes (MDS), which appears to improve...
ASH Directions

ASH Releases Clinical Practice Guidelines on SCD-Related Transfusion Support, Opens Access to LLS’ Clinical...

Sunday, March 1st, 2020
ASH Releases Clinical Practice Guidelines on Sickle Cell Disease-Related Transfusion Support The American Society of Hematology (ASH) has released new clinical practice guidelines on Sickle...
The Society Pages

David H. Koch Center Opens at MSKCC, Sidney Kimmel Welcomes Usama Gergis, and more

Sunday, March 1st, 2020
Patrick White Appointed Chair in Palliative Medicine and Supportive Care Patrick White, MD, director of the Division of Palliative Medicine at Washington University School of...

Evaluating Efgartigimod in Patients With Primary Immune Thrombocytopenia

Sunday, March 1st, 2020
Treatment with the neonatal Fc receptor antagonist efgartigimod led to clinically relevant increases in platelet counts in patients with primary immune thrombocytopenia (ITP), according...

Treatment With Four Cycles of R-CHOP Is Non-Inferior to Six Cycles in Some Aggressive...

Sunday, March 1st, 2020
For patients with aggressive B-cell non-Hodgkin lymphoma (NHL) and a favorable prognosis, treatment with four cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and...

March 2020 Issue

What’s a Life Worth and Who Gets to Decide?

Sunday, March 1st, 2020
In an ideal world, all patients would receive the best possible care regardless of cost. However, since wealth is unevenly distributed and there are...

Say Cheese: Kandice Marchant, MD, PhD

Sunday, March 1st, 2020
In this edition of pASHions, Kandice Marchant, MD, PhD, tells us about turning her love of cheesemaking into a business venture and the surprising similarities...

Pulling Back the Curtain: Amy DeZern, MD, MHS

Sunday, March 1st, 2020
In this edition, Amy DeZern, MD, MHS, talks about the life experience that cemented her desire to go into medicine and the value of...

March 2020 Issue

Maintenance of Certification: An Update on ABIM’s Evolving Requirements

Sunday, March 1st, 2020
Three decades ago, the American Board of Internal Medicine (ABIM) announced the end of the “board-certified-for-life” status that had been in place since the...
You Make the Call

You Make the Call: What is the best consolidation therapy for this patient with...

Sunday, March 1st, 2020
This month, Erin Reid, MD, discusses treatment of primary central nervous system lymphoma. And don't forget to check out next month's clinical dilemma - send...
How I Treat In Brief

How I Treat in Brief: Early Relapsing Follicular Lymphoma

Sunday, March 1st, 2020
Carla Casulo, MD, and Paul M. Barr, MD, from the Wilmot Cancer Institute at the University of Rochester Medical Center in New York, reviewed...